Shijiazhuang Pharmaceutical Group Receives EDQM Certification For Vitamin B12
This article was originally published in PharmAsia News
Executive Summary
Shijiazhuang Pharmaceutical Group has gained an on-site inspection certification for its vitamin B12 from the European Directorate for the Quality of Medicines, making it the first in China's vitamin B12 industry. The endorsement will allow China-made vitamin B12 to enter the high-end pharmaceutical field in 34 countries for manufacturing and sale. The potential market expansion and economic benefit represents major progress for local products which hitherto got little profit from the feedstuff and food industry. To avoid vicious competition in the low-end market, Shijiazhuang Pharmaceutical recently stepped up its international certification and registration efforts; it has already received EU Certificate of Suitability for six products - vitamin C, vitamin B12, caffeine, ranitidine, theophylline and amoxicillin. (Click her for more - Chinese Language)
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.